Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
caspofungin + efungumab + liposomal amphotericin B + voriconazole
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This is a combination of four antifungal agents with different mechanisms of action used for treating severe invasive fungal infections.
Components:
- Caspofungin: An echinocandin that inhibits fungal cell wall synthesis by targeting beta-(1,3)-D-glucan
- Efungumab: A human recombinant antibody against fungal heat shock protein 90 (hsp90)
- Liposomal amphotericin B: A liposomal formulation of amphotericin B that targets fungal ergosterol
- Voriconazole: A triazole antifungal that inhibits fungal ergosterol biosynthesis
This combination leverages multiple mechanisms to combat resistant fungal infections, particularly in immunocompromised patients. Studies have shown synergy between caspofungin and efungumab in treating Candida infections, and combinations of these antifungals have demonstrated efficacy in treating various invasive fungal infections.
02
Targets
Beyond the preview
Go deeper on caspofungin + efungumab + liposomal amphotericin B + voriconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on caspofungin + efungumab + liposomal amphotericin B + voriconazole.